{
  "id": "5c6e01af7c78d69471000048",
  "type": "list",
  "question": "List two indications of Letermovir?",
  "ideal_answer": "Letermovir is approved for the prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic haematopoietic stem cell transplant (HSCT).",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28675594",
    "http://www.ncbi.nlm.nih.gov/pubmed/30004790",
    "http://www.ncbi.nlm.nih.gov/pubmed/29578577",
    "http://www.ncbi.nlm.nih.gov/pubmed/28967706",
    "http://www.ncbi.nlm.nih.gov/pubmed/29290671",
    "http://www.ncbi.nlm.nih.gov/pubmed/29746444",
    "http://www.ncbi.nlm.nih.gov/pubmed/29914965",
    "http://www.ncbi.nlm.nih.gov/pubmed/29361041",
    "http://www.ncbi.nlm.nih.gov/pubmed/29288370",
    "http://www.ncbi.nlm.nih.gov/pubmed/29998227"
  ],
  "snippets": [
    {
      "text": "Latanoprostene bunod ophthalmic solution (Vyzulta) for the reduction of intraocular pressure; letermovir (Prevymis) for prophylaxis of cytomegalovirus infection and disease after stem cell transplant; benralizumab (Fasenra) for the add-on maintenance treatment of severe asthma of an eosinophilic phenotype.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29290671",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Letermovir has been approved in Canada and the USA for the prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic haematopoietic stem cell transplant (HSCT).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29288370",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This article summarizes the milestones in the development of letermovir leading to its first global approval in Canada as well as the USA for the prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic HSCT.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29288370",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A new terminase inhibitor, letermovir, recently proved effective against HCMV in phase III clinical trials, but the mechanism of action is unclear. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29361041",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Letermovir is being developed for human cytomegalovirus infection treatment and prophylaxis. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28967706",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Letermovir is a human cytomegalovirus terminase inhibitor for cytomegalovirus infection prophylaxis in hematopoietic stem cell transplant recipients. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29578577",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Role of letermovir for prevention of cytomegalovirus infection after allogeneic haematopoietic stem cell transplantation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29746444",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In this article, the role of the newly approved antiviral compound, letermovir, is reviewed.RECENT FINDINGS: Letermovir inhibits CMV by interfering viral terminase complex. In a phase 3 randomized placebo-controlled clinical study that enrolled 495 CMV-seropositive HSCT recipients, the primary end point of clinically significant CMV infection was significantly reduced by letermovir prophylaxis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29746444",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "SUMMARY: Letermovir is an important addition to the current strategies for CMV prevention after allogeneic HSCT. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29746444",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Letermovir is a human cytomegalovirus (CMV) terminase inhibitor recently approved as prophylaxis in stem cell transplant recipients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29914965",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Letermovir is a novel antiviral in clinical development for prophylaxis against human cytomegalovirus in immunocompromised transplant recipients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28675594",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Expert commentary: With the introduction of letermovir, prevention of CMV infection in allo-HCT recipients may shift considerably, from a predominantly preemptive strategy to one that utilizes this novel therapy for prophylaxis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30004790",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The positive results from the recently published Phase III study of letermovir for prevention of CMV infection in CMV-seropositive allo-HCT recipients led to its approval as a prophylactic agent for CMV in multiple countries.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30004790",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Letermovir has shown promising clinical efficacy and is generally well tolerated, thus providing a favorable new option in the prophylaxis of CMV infection and disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29998227",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "prophylaxis of CMV infection, CMV-seropositive recipients of an allogeneic haematopoietic stem cell transplant"
}